AAIC 2025 Abstract·26 DecPhase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease PatientsTrial in peopleInterventionsPaper